Changing how we talk about clinical trialsMultiple sclerosis (MS) patient Elizabeth Kinder tells us why she participated in a clinical trial and why the Share XChanging how we talk about clinical trialshttps://pharmaphorum.com/views-analysis-patients/changing-talk-clinical-trials-ms/
Biogen gears up for Alzheimer’s drug launchThere are serious doubts about whether the FDA will approve Biogen’s Alzheimer’s candidate aducanumab – but is gearing Share XBiogen gears up for Alzheimer’s drug launchhttps://pharmaphorum.com/news/biogen-gears-alzheimers/
Novartis’ Mayzent EU approval offers SPMS patients new optionNovartis’ Mayzent has been approved in Europe for adults with secondary progressive multiple sclerosis (SPMS) and active disease. Share XNovartis’ Mayzent EU approval offers SPMS patients new optionhttps://pharmaphorum.com/news/novartis-mayzent-eu-approval-offers-spms-patients-new-option/
NHS patients to get easier access to MS pill after NICE rethinkPatients in England are to get easier access to Merck KGaA’s multiple sclerosis drug Mavenclad after NICE dropped Share XNHS patients to get easier access to MS pill after NICE rethinkhttps://pharmaphorum.com/news/nhs-patients-to-get-easier-access-to-ms-pill-after-nice-rethink/
Brisk trade in risky three-drug ‘bet’ option after BMS/Celgene mergerBristol-Myers Squibb’s $74 billion merger with Celgene went ahead this week after clearance from US competition regulators, and Share XBrisk trade in risky three-drug ‘bet’ option after BMS/Celgene mergerhttps://pharmaphorum.com/news/celgene-shareholders/
Mavenclad helps Merck shrug off Rebif decline in MSAccelerating sales of Merck KGaA’s oral multiple sclerosis therapy Mavenclad helped the company to a double-digit rise in Share XMavenclad helps Merck shrug off Rebif decline in MShttps://pharmaphorum.com/news/mavenclad-helps-merck-shrug-off-rebif-decline-in-ms/
NICE backs NHS funding for two cannabis-based drugs for first timeNICE has recommended two of GW Pharma’s cannabis-based medicines, the first time that medicines derived from the plant Share XNICE backs NHS funding for two cannabis-based drugs for first timehttps://pharmaphorum.com/news/nice-includes-bayer-gws-cannabis-based-sativex-in-ms-guideline-for-first-time/
Sanofi settles dispute with Genzyme investors over MS drugSanofi has settled a long-running dispute with shareholders in the biotech Genzyme, who claimed the big pharma deliberately Share XSanofi settles dispute with Genzyme investors over MS drughttps://pharmaphorum.com/news/sanofi-settles-dispute-with-genzyme-investors-over-ms-drug/
Biogen bags FDA okay for Tecfidera follow-up VumerityBiogen’s multiple sclerosis franchise has been handed a boost with the US approval of Vumerity, a follow-up to Share XBiogen bags FDA okay for Tecfidera follow-up Vumerityhttps://pharmaphorum.com/news/biogen-fda-tecfidera-vumerity-ms/
